Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors, antagonists |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationSpecial Review Project (China) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Solid Tumors | Phase 1 | China | 21 Nov 2018 |





